Atrial fibrillation and the use of oral bisphosphonates

References

• BlackDMDelmasPDEastellRHORIZON Pivotal Fracture TrialOnce-yearly zoledronic acid for treatment of postmenopausal osteoporosisN Engl J Med20073561809182217476007
   PubMed Web of Science ®Google Scholar
• LylesKWColón-EmericCSMagazinerJSfor the HORIZON Recurrent Fracture TrialZoledronic Acid in Reducing Clinical Fracture and Mortality after Hip FractureN Engl J Med20073571799180917878149
   PubMed Web of Science ®Google Scholar
• PazianasMCooperCEbetinoFHRussellRGLong-term treatment with bisphosphonates and their safety in postmenopausal osteoporosisTher Clin Risk Manag2010632534320668715
   PubMed Web of Science ®Google Scholar
• CummingsSRSchwartzAVBlackDMAlendronate and atrial fibrillationN Engl J Med20073561895189617476024
   PubMed Web of Science ®Google Scholar
• KaramRCammJMcClungMYearly zoledronic acid in postmenopausal osteoporosisN Engl J Med200735771271317703529
   PubMed Web of Science ®Google Scholar
• LewieckiEMCooperCThompsonEHartlFMehtaDPapapoulosSEIbandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trialsInt J Clin Pract201064821826 Epub 2010 Mar 11.20337751
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA)The FDA safety information and adverse event reporting program Available at: http://www.fda.gov/medwatch/safety/2008/safety08.htm#bisphosphonates2. Accessed February 17, 2011.
   Google Scholar
• HeckbertSRLiGCummingsSRSmithNLPsatyBMUse of alendronate and risk of incident atrial fibrillation in womenArch Intern Med200816882683118443257
   PubMed Web of Science ®Google Scholar
• SørensenHTChristensenSMehnertFUse of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control studyBMJ200833681381618334527
   PubMed Web of Science ®Google Scholar
• AbrahamsenBEikenPBrixenKAtrial fibrillation in fracture patients treated with oral bisphosphonatesJ Intern Med200926558159219141097
   PubMed Web of Science ®Google Scholar
• GrossoADouglasIHingoraniAMacAllisterRSmeethLOral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysisPLoS ONE20094e4720 Epub 2009 Mar 619266096
   PubMed Web of Science ®Google Scholar
• LokeYKJeevananthamVSinghSBisphosphonates and atrial fibrillation: systematic review and meta-analysisDrug Saf20093221922819338379
   PubMed Web of Science ®Google Scholar
• BhuriyaRSinghMMolnarJAroraRKhoslaSBisphosphonate use in women and the risk of atrial fibrillation: a systematic review and meta-analysisInt J Cardiol2010142213217 Epub 2010 Jan 3.20051297
   PubMed Web of Science ®Google Scholar
• PazianasMCompstonJHuangCLAtrial fibrillation and bisphosphonate therapyJ Bone Miner Res20102521020091928
   PubMed Web of Science ®Google Scholar
• VandenbrouckeJPWhen are observational studies as credible as 11 randomised trials?Lancet20043631728173115158638
   PubMed Web of Science ®Google Scholar
• MajumdarSROral bisphosphonates and atrial fibrillationBMJ2008336784785 Epub 2008 Mar 11.18334526
   PubMed Web of Science ®Google Scholar
• KannelWBWolfPABenjaminEJLevyDPrevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimatesAm J Cardiol1998828A2N9N
   PubMed Web of Science ®Google Scholar
• RuigómezAJohanssonSWallanderMARodríguezLAIncidence of chronic atrial fibrillation in general practice and its treatment patternJ Clin Epidemiol20025535836311927203
   PubMed Web of Science ®Google Scholar
• AdamsonDMChangSHansenLGHealth research data for the real world: the Marketscan databasesNew YorkThompson Healthcare2008
   Google Scholar
• LewisJDSchinnarRBilkerWBWangXStromBLValidation studies of the health improvement network (THIN) database for pharmacoepidemiology researchPharmacoepidemiol Drug Saf20071639340117066486
   PubMed Web of Science ®Google Scholar
• ShtatlandESKleinmanKCainEMModel building in Proc Phreg with automatic variable selection and information criteria Online proceedings paper, SAS Users Global Forum 2005 Available at: http://www2.sas.com/proceedings/sugi30/206-30.pdf. Accessed February 17, 2011.
   Google Scholar
• MiyasakaYBarnesMEGershBJSecular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalenceCirculation2006711114119125 Epub 2006 Jul 3. Erratum in: Circulation. 2006;114:e498.17192512
   PubMed Web of Science ®Google Scholar
• SavelievaICammAJClinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and managementJ Interv Card Electrophysiol2000436938210936003
   PubMed Web of Science ®Google Scholar
• BlackDMDelmasPDEastellRHORIZON Pivotal Fracture TrialOnce-yearly zoledronic acid for treatment of postmenopausal osteoporosisN Engl J Med200735618091822 Comment in 2007;35:713; author reply 714–71517476007
   PubMed Web of Science ®Google Scholar
• CauleyJAEnsrudKEConsidering competing risks … Not all black and whiteArch Intern Med200816879379518443252
   PubMedGoogle Scholar
• BoosCJLipGYInflammation and atrial fibrillation: cause or effect?Heart20089413313418195117
   PubMed Web of Science ®Google Scholar
• SantiniDFrattoMEVincenziBLa CesaADianzaniCToniniGBisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activitiesBioDrugs20041826927815244502
   PubMed Web of Science ®Google Scholar
• HewittRELissinaAGreenAESlayESPriceDASewellAKThe bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statinsClin Exp Immunol200513910111115606619
   PubMed Web of Science ®Google Scholar
• AvilesRJMartinDOApperson-HansenCInflammation as a risk factor for atrial fibrillationCirculation20031083006301014623805
   PubMed Web of Science ®Google Scholar
• ChristiansenCFChristensenSMehnertFCummingsSRChapurlatRDSørensenHTGlucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control studyArch Intern Med20091691677168319822824
   PubMed Web of Science ®Google Scholar
• PerrioMVossSShakirSAApplication of the bradford hill criteria to assess the causality of cisapride-induced arrhythmia: a model for assessing causal association in pharmacovigilanceDrug Saf20073033334617408310
   PubMed Web of Science ®Google Scholar
• TankoLBChristiansenCCoxDAGeigerMJMcNabbMACummingsSRRelationship between osteoporosis and cardiovascular disease in postmenopausal womenJ Bone Miner Res2005201912192016234963
   PubMed Web of Science ®Google Scholar